299 related articles for article (PubMed ID: 20016813)
41. Nanobody-targeted photodynamic therapy induces significant tumor regression of trastuzumab-resistant HER2-positive breast cancer, after a single treatment session.
Deken MM; Kijanka MM; Beltrán Hernández I; Slooter MD; de Bruijn HS; van Diest PJ; van Bergen En Henegouwen PMP; Lowik CWGM; Robinson DJ; Vahrmeijer AL; Oliveira S
J Control Release; 2020 Jul; 323():269-281. PubMed ID: 32330574
[TBL] [Abstract][Full Text] [Related]
42. Eradication of growth of HER2-positive ovarian cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate in mouse xenograft model.
Yu L; Wang Y; Yao Y; Li W; Lai Q; Li J; Zhou Y; Kang T; Xie Y; Wu Y; Chen X; Yi C; Gou L; Yang J
Int J Gynecol Cancer; 2014 Sep; 24(7):1158-64. PubMed ID: 24987913
[TBL] [Abstract][Full Text] [Related]
43. Targeted antitumor efficacy and imaging via multifunctional nano-carrier conjugated with anti-HER2 trastuzumab.
Choi WI; Lee JH; Kim JY; Heo SU; Jeong YY; Kim YH; Tae G
Nanomedicine; 2015 Feb; 11(2):359-68. PubMed ID: 25262581
[TBL] [Abstract][Full Text] [Related]
44. Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth.
Chandarlapaty S; Scaltriti M; Angelini P; Ye Q; Guzman M; Hudis CA; Norton L; Solit DB; Arribas J; Baselga J; Rosen N
Oncogene; 2010 Jan; 29(3):325-34. PubMed ID: 19855434
[TBL] [Abstract][Full Text] [Related]
45. [Herceptin-based therapy for breast cancer].
Tokuda Y; Saito Y; Suzuki Y
Nihon Rinsho; 2006 Mar; 64(3):540-5. PubMed ID: 16529047
[TBL] [Abstract][Full Text] [Related]
46. Near-Infrared Photochemoimmunotherapy by Photoactivatable Bifunctional Antibody-Drug Conjugates Targeting Human Epidermal Growth Factor Receptor 2 Positive Cancer.
Ito K; Mitsunaga M; Nishimura T; Saruta M; Iwamoto T; Kobayashi H; Tajiri H
Bioconjug Chem; 2017 May; 28(5):1458-1469. PubMed ID: 28402624
[TBL] [Abstract][Full Text] [Related]
47. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.
Scaltriti M; Rojo F; Ocaña A; Anido J; Guzman M; Cortes J; Di Cosimo S; Matias-Guiu X; Ramon y Cajal S; Arribas J; Baselga J
J Natl Cancer Inst; 2007 Apr; 99(8):628-38. PubMed ID: 17440164
[TBL] [Abstract][Full Text] [Related]
48. In vitro and in vivo studies of the combination of IGF1R inhibitor figitumumab (CP-751,871) with HER2 inhibitors trastuzumab and neratinib.
Chakraborty AK; Zerillo C; DiGiovanna MP
Breast Cancer Res Treat; 2015 Aug; 152(3):533-44. PubMed ID: 26195122
[TBL] [Abstract][Full Text] [Related]
49. Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts.
du Manoir JM; Francia G; Man S; Mossoba M; Medin JA; Viloria-Petit A; Hicklin DJ; Emmenegger U; Kerbel RS
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):904-16. PubMed ID: 16467105
[TBL] [Abstract][Full Text] [Related]
50. Combination of adoptive immunotherapy with Herceptin for patients with HER2-expressing breast cancer.
Kubo M; Morisaki T; Kuroki H; Tasaki A; Yamanaka N; Matsumoto K; Nakamura K; Onishi H; Baba E; Katano M
Anticancer Res; 2003; 23(6a):4443-9. PubMed ID: 14666732
[TBL] [Abstract][Full Text] [Related]
51. A new anti-HER2 antibody that enhances the anti-tumor efficacy of trastuzumab and pertuzumab with a distinct mechanism of action.
Zhang X; Chen J; Weng Z; Li Q; Zhao L; Yu N; Deng L; Xu W; Yang Y; Zhu Z; Huang H
Mol Immunol; 2020 Mar; 119():48-58. PubMed ID: 31978707
[TBL] [Abstract][Full Text] [Related]
52. Quantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patients.
Sperinde J; Jin X; Banerjee J; Penuel E; Saha A; Diedrich G; Huang W; Leitzel K; Weidler J; Ali SM; Fuchs EM; Singer CF; Köstler WJ; Bates M; Parry G; Winslow J; Lipton A
Clin Cancer Res; 2010 Aug; 16(16):4226-35. PubMed ID: 20664024
[TBL] [Abstract][Full Text] [Related]
53. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer.
Goldenberg MM
Clin Ther; 1999 Feb; 21(2):309-18. PubMed ID: 10211534
[TBL] [Abstract][Full Text] [Related]
54. Trastuzumab treatment in patients with breast cancer and metastatic CNS disease.
Pieńkowski T; Zielinski CC
Ann Oncol; 2010 May; 21(5):917-24. PubMed ID: 19717536
[TBL] [Abstract][Full Text] [Related]
55. Trastuzumab derived HER2-specific CARs for the treatment of trastuzumab-resistant breast cancer: CAR T cells penetrate and eradicate tumors that are not accessible to antibodies.
Szöőr Á; Tóth G; Zsebik B; Szabó V; Eshhar Z; Abken H; Vereb G
Cancer Lett; 2020 Aug; 484():1-8. PubMed ID: 32289441
[TBL] [Abstract][Full Text] [Related]
56. Bispecific anti-HER2 and CD16 single-chain antibody production prolongs the use of stem cell-like cell transplantation against HER2-overexpressing cancer.
Kasuya K; Shimazu M; Suzuki M; Itoi T; Aoki T; Tsuchida A
Int J Mol Med; 2010 Feb; 25(2):209-15. PubMed ID: 20043129
[TBL] [Abstract][Full Text] [Related]
57. Suppression of tumor growth in human gastric cancer with HER2 overexpression by an anti-HER2 antibody in a murine model.
Matsui Y; Inomata M; Tojigamori M; Sonoda K; Shiraishi N; Kitano S
Int J Oncol; 2005 Sep; 27(3):681-5. PubMed ID: 16077916
[TBL] [Abstract][Full Text] [Related]
58. Intrathecal Viral Vector Delivery of Trastuzumab Prevents or Inhibits Tumor Growth of Human HER2-Positive Xenografts in Mice.
Rothwell WT; Bell P; Richman LK; Limberis MP; Tretiakova AP; Li M; Wilson JM
Cancer Res; 2018 Nov; 78(21):6171-6182. PubMed ID: 30154145
[TBL] [Abstract][Full Text] [Related]
59. Anti-HER2 immunoliposomes for co-delivery of paclitaxel and rapamycin for breast cancer therapy.
Eloy JO; Petrilli R; Chesca DL; Saggioro FP; Lee RJ; Marchetti JM
Eur J Pharm Biopharm; 2017 Jun; 115():159-167. PubMed ID: 28257810
[TBL] [Abstract][Full Text] [Related]
60. The level of insulin growth factor-1 receptor expression is directly correlated with the tumor uptake of (111)In-IGF-1(E3R) in vivo and the clonogenic survival of breast cancer cells exposed in vitro to trastuzumab (Herceptin).
Cornelissen B; McLarty K; Kersemans V; Reilly RM
Nucl Med Biol; 2008 Aug; 35(6):645-53. PubMed ID: 18678349
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
